Search - tctmd.com

Displaying 361 - 380 of 648

Sort: Relevancy | Date

Presentation TCT 2015

How Did I Treat a High Surgical Risk Patient With Bicuspid Aortic Valve Stenosis?

Presenter: Run-Lin Gao, Martin B. Leon, Bo Xu, Yongjian Wu

October 11, 2015

Presentation TCT 2015

How Would I Treat a High Surgical Risk Patient With Bicuspid Aortic Valve Stenosis?

Presenter: Run-Lin Gao, Martin B. Leon, Bo Xu, Mao Chen

October 11, 2015

Presentation TCT 2015

How Should I Treat a High Surgical Risk Patient With Bicuspid Aortic Valve Stenosis?

Presenter: Run-Lin Gao, Martin B. Leon, Bo Xu, Yongjian Wu

October 11, 2015

Presentation TCT 2015

Lessons From the EU TAVR Registries 3: FRANCE 2 (and More)

Presenter: Samir R. Kapadia, Jeffrey J. Popma, Martin B. Leon

October 11, 2015

Presentation TCT 2015

Status Updates on New TAVR Indications 5: Predominant Aortic Regurgitation

Presenter: Martin B. Leon, Neil E. Moat, Hendrik Treede

October 11, 2015

Presentation TCT 2015

Status Updates on New TAVR Indications 4: Aortic Stenosis + Mitral Regurgitation

Presenter: Martin B. Leon, Neil E. Moat, Simon Redwood

October 11, 2015

Presentation TCT 2015

Status Updates on New TAVR Indications 3: Aortic Stenosis + Coronary Artery

Presenter: Martin B. Leon, Neil E. Moat, David Hildick-Smith

October 11, 2015

Presentation TCT 2015

Status Updates on New TAVR Indications 2: Low-Flow (Low-Gradient) AS

Presenter: Martin B. Leon, Neil E. Moat, Howard C. Herrmann

October 11, 2015

Presentation TCT 2015

Status Updates on New TAVR Indications 1: Bicuspid Aortic Valve Disease

Presenter: Martin B. Leon, Neil E. Moat, John G. Webb

October 11, 2015

Presentation TCT 2015

KEYNOTE LECTURE: Transcatheter Valve Replacement for Bioprosthetic Valve Failure Gold Standard vs Selective Application (The VIVID Registry)

Presenter: Martin B. Leon, Neil E. Moat, Danny Dvir

October 11, 2015

Presentation TCT 2015

Predicting the Future of Open Surgery for Aortic Stenosis: The TAVR Effect

Presenter: Martin B. Leon, Neil E. Moat

October 11, 2015

Presentation TCT 2015

Status Update on Moderate-Risk TAVR RCTs 2: SURTAVI

Presenter: Martin B. Leon, Neil E. Moat, Patrick W. Serruys

October 11, 2015

Presentation TCT 2015

Status Update on Moderate-Risk TAVR RCTs 1: PARTNER IIA

Presenter: Martin B. Leon, Neil E. Moat

October 11, 2015

Presentation TCT 2015

The Case for TAVR Expansion to Lower-Risk Patients

Presenter: Martin B. Leon, Neil E. Moat, Nicolo Piazza

October 11, 2015

Presentation TCT 2015

Which Aortic Stenosis Patients Are Definitely NOT TAVR Candidates in 2015?

Presenter: Martin B. Leon, Neil E. Moat, Thomas Walther

October 11, 2015

Presentation TCT 2015

What Are the Indications for TAVR in 2015? According to Real-World Clinical Practice

Presenter: Martin B. Leon, Neil E. Moat, Axel Linke

October 11, 2015

Presentation TCT 2015

What Are the Indications for TAVR in 2015? According to the EU and US Guidelines

Presenter: Martin B. Leon, Neil E. Moat, Alec S. Vahanian

October 11, 2015

Presentation TCT 2015

Introduction

Presenter: Eberhard Grube, Michael J. Mack, Martin B. Leon

October 11, 2015

News Conference News TCT 2015

Global TAVR Market Poised to Exceed DES Market by 2025

October 11, 2015

News Daily News

在人工动脉瓣中二尖瓣运动降低并不少见，但可通过抗凝予以治疗

L.A. McKeown

October 08, 2015

Advertisement

How Did I Treat a High Surgical Risk Patient With Bicuspid Aortic Valve Stenosis?

How Would I Treat a High Surgical Risk Patient With Bicuspid Aortic Valve Stenosis?

How Should I Treat a High Surgical Risk Patient With Bicuspid Aortic Valve Stenosis?

Lessons From the EU TAVR Registries 3: FRANCE 2 (and More)

Status Updates on New TAVR Indications 5: Predominant Aortic Regurgitation

Status Updates on New TAVR Indications 4: Aortic Stenosis + Mitral Regurgitation

Status Updates on New TAVR Indications 3: Aortic Stenosis + Coronary Artery

Status Updates on New TAVR Indications 2: Low-Flow (Low-Gradient) AS

Status Updates on New TAVR Indications 1: Bicuspid Aortic Valve Disease

KEYNOTE LECTURE: Transcatheter Valve Replacement for Bioprosthetic Valve Failure Gold Standard vs Selective Application (The VIVID Registry)

Predicting the Future of Open Surgery for Aortic Stenosis: The TAVR Effect

Status Update on Moderate-Risk TAVR RCTs 2: SURTAVI

Status Update on Moderate-Risk TAVR RCTs 1: PARTNER IIA

The Case for TAVR Expansion to Lower-Risk Patients

Which Aortic Stenosis Patients Are Definitely NOT TAVR Candidates in 2015?

What Are the Indications for TAVR in 2015? According to Real-World Clinical Practice

What Are the Indications for TAVR in 2015? According to the EU and US Guidelines

Introduction

Global TAVR Market Poised to Exceed DES Market by 2025

在人工动脉瓣中二尖瓣运动降低并不少见，但可通过抗凝予以治疗

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content